Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA Mounjaro reset refers to stopping treatment temporarily and restarting it, usually from the lowest dose. Whether that's planned by a prescriber or happens because supply ran out, the core question is the same: does the medicine behave differently on a restart? The short answer is yes, in practical terms, your body's response to the dose schedule typically mirrors what happened the first time around. Mounjaro is a prescription-only medicine — any decision to stop, pause or restart should be made with a prescriber, not independently.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works by activating two gut-hormone receptors simultaneously (GIP and GLP-1) which together slow how quickly the stomach empties and reduce appetite signalling between the gut and brain. Once you stop taking it, that dual signal fades. For most people, hunger returns within days to weeks as the medicine clears the body, and the biological drive to eat increases again.
This is not a personal failure. The clinical trial data from SURMOUNT-1, published in the New England Journal of Medicine, showed that weight regain began in extension periods when participants moved to placebo, reflecting exactly this pattern. The medicine addresses underlying appetite physiology; pausing it removes that effect. Some people lose a meaningful amount of ground over a gap of several weeks. Others maintain weight for a month or two, particularly if the dietary habits built during treatment hold. The outcome varies, and a prescriber can give you a clearer picture based on your own history.
If you want to understand more about how tirzepatide's mechanisms translate into clinical outcomes, you can read about how Mounjaro works alongside the evidence behind Mounjaro, which covers the trial programme in detail.
A full reset (back to 2.5 mg) is the standard clinical starting point after any significant gap in treatment. The reason is straightforward: tolerance to the side-effect profile (mainly gastrointestinal symptoms like nausea and reflux) diminishes when the medicine is absent, so jumping back to a higher dose risks the kind of nausea, vomiting or diarrhoea that causes people to abandon treatment altogether.
How long a gap triggers a full reset depends on the prescriber's judgement, though many use a few weeks as the threshold. Shorter gaps (a missed pen here or there) are handled differently; you can read more about the day-to-day effects of dosing changes in this overview of what happens when Mounjaro doses change. A gap caused by supply issues, a holiday, a hospital stay, or simply running out before a payday can all require the same clinical conversation. It is worth flagging this early: at nume, the aftercare team is available seven days a week specifically for situations like this.
The prescriber will also want to know about any changes to your health since you last took the medicine: new diagnoses, new medications, significant changes in weight. These affect what dose is appropriate now, not just what you were on before.
No. A reset is a titration decision, not a verdict on whether Mounjaro suited you. The documented effects of tirzepatide on appetite and body weight are consistent across restarts in clinical practice, and there is no evidence that a previous course makes the medicine less effective on re-exposure.
What does change is the starting point. If significant weight has been regained, the amount of work ahead is larger, but the mechanism of the medicine is unchanged. Prescribers at regulated UK services typically review weight evidence at the restart consultation, which is one reason the full consultation process covers current weight alongside medical history. At nume's pharmacy, that re-review happens before each repeat regardless of whether a break has occurred, as a routine clinical check rather than an added hurdle.
One thing worth knowing: some people experience stronger initial side effects on a restart than they did the first time, possibly because prior exposure to a higher dose has reset expectations. Going slowly through the dose schedule matters even more if that applies to you. The stomach side effects section covers what to expect and when symptoms warrant contacting a prescriber.
If you are transferring to a new pharmacy after a break, or restarting after a clinical pause, a re-assessment is required by any responsibly run service. At nume, this mirrors the initial consultation: a GPhC-registered Independent Prescriber reads your submission personally. You will be asked about the length of your break, any weight change, current health status and any other medicines you have started since your last prescription.
For context on what that consultation involves and what prices look like for a private prescription, the Mounjaro cost page explains the full picture of what a private prescription typically includes. Once the prescriber is satisfied that a restart is clinically appropriate, treatment is dispatched the same day for orders placed before 12pm, arriving the next working day via DPD. The packaging is plain and unbranded. Our clinical team's approach is designed so that a gap in treatment does not have to mean a long wait to get back on track.
The NHS tirzepatide page is a reliable source for further reading on how the medicine works and what to discuss with a prescriber before any change: NHS tirzepatide information. If you have specific questions about your situation, speaking to our prescribers is the right first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.